PDA IB Lecture 9, 10, 11, 12: Dose-Response Curves: Agonists and Antagonists

Ligand/Drug Classification (3)

1. Agonist (full & partial)

2. Antagonist (competitive & allosteric)

3. Inverse agonist

Exogenous agonist

initiates a response when it binds to receptor (activates the receptor)

Endogenous agonists

binds to receptors and mimics the effects of the endogenous compound

(neurotransmitters, hormones, etc.)

Antagonist

drug that interferes with or inhibits action by binding/blocking a receptor rather than activating it.

T/F: Antagonist activity may be reversible or irreversible depending on the longevity of the antagonist–receptor complex, which depends on the nature of antagonist–receptor binding

TRUE

- Agonists bind to a receptor and ______________

- Antagonists bind to a receptor but ______________________________

- activate it

- would not activate it

Affinity******

the ability of an agonist/antagonist to bind to a receptor

- how well a drug and receptor recognize each other

Efficacy ******

the ability of an agonist to activate a receptor

- maximal effect an agonist can achieve at the highest practical concentration

[D/L] =

[R] =

[DR/LR] =

[D/L] = drug/ligan

[R] = receptor

[DR/LR] = drug-receptor complex

Is the binding of a functional group to a receptor a reversible reaction?

YES

Ligand/drug affinity equation

What is K+1?

What is K-1?

K+1 = Association rate

K-1 = Dissociation rate

What is the reversible formation of the ligand-receptor complex LR governed by?

the chemical property of affinity

High-affinity ligand binding results from....

greater attractive forces between the ligand and its receptor

Low-affinity ligand binding involves less...

less attractive forces

Pharmacophore

structural feature (or chemistry) of the drug that interacts with the ligand binding pocket of a specific receptor

k+1[L][R] = k-1[LR]

What is (k+1[L][R])?

What is (k-1[LR])?

(k+1[L][R]) = formation of ligand-receptor complex [LR]

(k-1[LR]) = dissociation of LR into L and R

Equilibrium dissociation constant KD

At equilibrium, KD corresponds to the ligand concentration [L] at which half of the receptor are occupied

KD = [L]

The affinity constant/equilibrium association constant KA

reciprocal of the equilibrium dissociation constant

(likelihood of drug to associate with receptor)

KD units****

concentration units

Ex: 1 M, 1 mM, 1 mcM, etc.

KA units***

1/concentration units

Ex: M-1, mM-1, etc.

Lower KD (or higher KA values) has...

- higher affinity

- difficult to dissociate (hours)

Higher KD (or lower KA values) has...

- lower affinity

- dissociates quickly (seconds)

Ligand-binding hyperbolic curve graph

RT= Total receptor

RL = Receptor binding ligand complex

Kd = Dissociation constant

Receptor-ligand sigmoidal curve graph

In log, you need to reverse log. LogKd is NOT actual Kd. (have to reverse log)

- B = receptor sites bound drugs

- Bmax = total concentration of receptor sites

- KD = dissociation constant

What is the drug-receptor interaction characterized by? (2)

(1) binding of drug to receptor

(2) generation of a response in a biological system

What is a crucial factor in determining drug efficacy?

the reversible formation of the ligand-activated receptor complex (LR*)

Efficacy refers to the highest...

the level of response achievable by a drug

Ligand/Drug Affinity and Efficacy Equation

K+1 = activation rate

K-2 = deactivation rate

EC50

effective concentration of agonist for 50% of the maximal response

IC50

antagonist concentration of an inhibitor that produces 50% of binding inhibition

Potency

the amount of agonist needed to elicit a desired response

T/F: Potency of an agonist is inversely related to its EC50 value

TRUE

According to the graph, is Drug X or Drug Y more potent?

Drug X is more potent

- its EC50 occurs with less amount of drug

Efficacy is a measure of how well a drug produces a ________________ shown by _____________ reached by the curve

- response

- maximal height

According to the graph, which has higher efficacy; Drug X or Drug Y?

in terms of efficacy, they are equivalent

Does Drug X or Drug Y have higher relative efficacy?

Drug X is more effective than drug Y

- drug X is more potent than Y

Full agonists

elicit a maximal response

- can induce a conformational change leading to maximal effect

Partial agonist

can activate receptor, but are unable to elicit a maximal response

- can induce some degree of receptor activation but not of sufficiently

Which drug is more potent in this graph? Which has higher efficacy?

- Drug X is more potent

- Drug X is the same as drug Y

...

...

The maximum response that can be produced by the partial agonist is _________ than _____________ of the max response of the system

less than 100%

T/F: The maximal response of a partial agonist is higher than that of a full agonist

FALSE

the max response of a full agonist is higher

Do full agonists or partial agonists have a greater efficacy?

full agonists

What happens if a partial agonist drug and a full agonist drug are used at the same time?

the partial agonist will act as an antagonist, competing with the full antagonist for binding sites

of the binding sites occupied by the partial agonist, some will not be ______________ which reduces the ____________________

- activated

- total drug effect

How can a maximal system response still be achieved?

the partial agonist can be displaced from the receptor by a sufficiently high concentration of full agonist

(unless partial agonist binds irreversibly)

In the presence of both a full and partial agonist, the efficacy of the full agonist is __________________, but its potency is ______________

- not affected

- reduced

(in graph, still reaches max response, but Ec50 is shifted to the right)

(Look at graph) Which drugs are more potent?

Drug A is more potent than drug C, drug B is more potent than drug C

- no comparisons of potency can be made between drugs A and B because one is a partial agonist, the other is a full agonist

At low responses, are partial agonists or full agonists more potent? At high responses?

- at low responses, partial agonists are more potent?

- at high responses, full agonists are more potent

T/F: Affinity of a full agonist is always higher than that of a partial agonist

FALSE

affinity of a partial agonist can be higher

At low concentrations, is the partial agonist more potent than the full agonist?

YES

(in graph, the dose of the partial agonist needed to achieve 20% of max response is lower than that of the full agonist)

T/F: No matter how high the dose of a partial agonist is, it can never reach max response

TRUE

What does increasing the concentration of a partial agonist do?

inhibits the binding of a full agonist

Once enough of the partial agonist is added it completely....

displaces the full agonist from receptor binding sites

As the partial agonist displaces the full agonist from the receptor, the response is reduced-the partial agonist is acting as an....

antagonist

(graph shows effect of increasing doses of the partial agonist on the maximal response from pretreatment of full agonist)

Increasing concentrations of a partial agonist......

decreases the response of full agonist

Biased agonists

stabilize receptor conformation preferentially stimulating one of the pathways, allowing for more targeted modulation of cell function/disease treatment

Biased agonism is most extensively characterized at what?

G protein coupled receptors (GPCRs)

Biased agonism: For GPCRs, the subset is either the ________________ mediated signaling events or the _____________ but NOT ___________________________

- β-arrestin

- Gα events

- both pathways simultaneously

Inverse agonist

ligand that binds to a receptor, producing the opposite effect that would be produced when an agonist binds the same receptor

inverse agonists _________ the intrinsic activity of the free (unoccupied) receptor

abrogate (gets rid of)

Inverse agonists are linked/tied to a certain pool of receptors that exhibit measurable level of ________________________ in the absence of ________________

- constitutive activity

- agonist stimulation

Inverse agonist will not have any effect in a _______________, since there is no activity to ____________ the absence of agonist

- pure induction model

- inhibit

Only if there is a certain _______________________, will an inverse agonist have an effect

"baseline" level of activity

Agents that bind to the agonist binding sites, stabilizing the receptor in its inactive conformational state leading to....

receptor inactivation, lowering the receptors "basal activity"

Inverse agonism: the 2 conformational states of receptor

- Active (R3)

- Inactive (Ri)

An agonist binds with higher affinity to ________ than ________ = response

(Ra) than (Ri)

An inverse agonist binds with higher affinity to _________ than ________ and will shift _______________ in other direction

(Ri) than (Ra)

- equilibrium

Both inverse agonists and agonists can be blocked by....

antagonists

Neutral antagonist

has no activity in the absence of an agonist or inverse agonist, but can block the activity of either

....

....

Two major types of antagonists

- competitive antagonist

- noncompetitive antagonist

What is a competitive antagonist?

Does is show pharmacological effect?

What is its inhibition mediated by?

antagonists that bind to the same binding sites as agonists, inhibiting its binding/effect

Shows no pharmacological effect on the receptor by itself (lacks intrinsic activity)

mediated by a steric mechanism

How can the effect of a competitive antagonist be reversed (or surmounted?

by increasing the concentration of the agonist

(a competitive antagonist increases the agonist concentration required for a given response)

When the full agonist is present with a fixed concentration of competitive antagonist, the potency of the agonist is __________, but the maximum efficacy _______________

reduced, but the maximum efficacy is not

(similar effect as a partial agonist)

Knowing IC50, what can we calculate?

the Ki (inhibition constant)

When there is just one binding site, what does Ki equal?

Ki = Kd

When drug I (competitive antagonist) is present at increasing concentrations, it is necessary to apply ___________________ of drug A (agonist) to obtain the ______________________

- higher concentrations

- same maximal effect (shift to the right)

The EC50 of drug A increases ________________ with the concentration of drug I

linearly

Key features of a competitive antagonist:

- _______________ binding to the receptor

- blockade can be overcome by.......

- the maximal response of the agonist is not __________________

- reversible

- increasing the agonist concentration

- not decreased

The agonist dose-response curve in the presence of a competitive antagonist is shifted ____________ to the right with no

____________________________________

- parallel

- no change in the maximal response

Noncompetitive antagonists (allosteric antagonists)

bind irreversibly to sites different from the agonist binding site(s) but inhibit the receptor function

- mediated by an allosteric mechanism

T/F: noncompetitive antagonists compete for the same binding site as agonists

FALSE

do NOT compete for same sites

The bound noncompetitive antagonist may prevent....

conformational changes in the receptor required for receptor activation

Do noncompetitive antagonists decrease an agonist's maximal effect?

YES

they decrease agonist maximal effect

- their effect is the same as removing receptors from the system

- reduce the # of receptors available to be activated

T/F: The actions of noncompetitive antagonists CAN be overcome by increasing the dose of agonist

FALSE

their actions CANNOT be overcome by increasing the dose

How do noncompetitive antagonists shift the sigmoidal curve of a full agonist?

shifts it downward and to the right

How do competitive antagonists shift the sigmoidal curve of a full agonist?

shifts to the right

In the case of an allosteric antagonist, the affinity of the receptor for the agonist is....

decreased by the antagonist

(there is a decrease in the max. response, shifts right and downward)

What is a noncompetitive agonist?

Drugs that bind to site(s) different from the agonist site(s) but enhance the agonist-activated receptor

- mediated by an allosteric mechanism

In the presence of increasing concentrations of drug P (co-agonist), the maximal effect of drug A (agonist) is reached at lower concentrations (left-shifted or potentiation)

curve shifts upward and to the left

Irreversible antagonist

- chemically reactive compound, covalently binds with receptor

- receptor is irreversibly inactivated, blockade cannot be overcome with increasing agonist conc.

- shifts the agonist dose-curve to the right and depresses maximal responsiveness

(same as noncompetitive)

Chemical antagonist

- does not involve a receptor

- drug inactivates other drug by directly binding to the second drug (ex: chelator/sequester)

(heparin and protamine sulfate; portamine sul. inactivates heparin)

Physiological antagonist

drug that activates a receptor/pathway with an intrinsic activity=1 and is opposed to the pharmacological action of the drug of interest

Physiological antagonist: there are 2 agonists, but each binds to its own _____________________, and they produce _________________________________

- receptor

- opposing effects

Antagonist Classification/Summary Diagram

Graph of relative affinity of drugs

Graded-dose curve graph example: potentiation vs. antagonism

- competitive shifts to the right

- competitive shifts downward and right

.....

.....

Synergism

the combined effect of two drugs is higher than the sum of their individual effects

(ex: not 1 + 1 = 2, it is 1 + 1 > 2)